Medicus Pharma Ltd. Common Stock (MDCX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Medicus Pharma Ltd. Commo... (MDCX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.60

0.02 (0.78%)

At close: Jan 15, 2025, 11:18 AM

undefined% (undefined)

Bid	2.4
Market Cap	30.72M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.88
PE Ratio (ttm)	-2.95
Forward PE	n/a
Analyst	Buy

Ask	3
Volume	11,604
Avg. Volume (20D)	34,587
Open	2.68
Previous Close	2.58
Day's Range	2.46 - 2.83
52-Week Range	1.80 - 3.23
Beta	undefined

About MDCX

A detailed description of the company is not yet available....

[Show more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange NASDAQ

Ticker Symbol MDCX

Analyst Forecast

According to 1 analyst ratings, the average rating for MDCX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 284.63% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 month ago · Source

Medicus Pharma shares are trading higher after the... Unlock content with Pro Subscription

News

3 weeks ago · proactiveinvestors.com

Medicus Pharma CEO charts course for 2025 with clinical milestones for SkinJect

Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX), a biotechnology company specializing in non-invasive dermatological treatments, is gearing up for a pivotal year in 2025. The company is advancing SkinJect, i...

3 weeks ago · proactiveinvestors.com

Medicus Pharma achieves FDA MUMS approval for equine squamous cell carcinoma patch - ICYMI

Earlier this week Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) announced that its innovative skin patch treatment has received Minor Use and Minor Species (MUMS) designation from the FDA. The patch, which...

1 month ago · proactiveinvestors.com

Medicus Pharma's horse skin cancer treatment wins MUMS designation from FDA

Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) announced that the Food and Drug Administration has granted Minor Use in Major Species (MUMS) designation for its Investigational New Animal Drug, a dissolvabl...

1 month ago · newsfilecorp.com

Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch

Company to Submit Product Development Plan to Treat External Squamous Cell Carcinoma (SCC) in Horses Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - December 12, 2024) - Medicus Pha...

1 month ago · proactiveinvestors.com

Medicus Pharma CEO on basal-cell carcinoma trial progress – ICYMI

Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) provided an update on its phase two clinical trial for a novel non-invasive treatment targeting basal-cell carcinoma. CEO Raza Bokhari told Proactive that 25%...

1 month ago · proactiveinvestors.com

Medicus Pharma eyes pivotal trial for novel skin cancer therapy as Phase 2 enrollment progresses

Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) announced that its Phase 2 clinical study targeting basal cell carcinoma (BCC) is now being conducted at nine clinical sites across the United States, with mor...

1 month ago · proactiveinvestors.com

Medicus Pharma partners with Swanielle to expand basal cell carcinoma study into Asia-Pacific

Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) announced it has entered into an agreement with healthcare consulting firm Swanielle to explore expanding its Phase 2 clinical study for treating Basal Cell Ca...

1 month ago · newsfilecorp.com

Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region

Provides Update on SKNJCT-003 Phase 2 Clinical Study for Treatment of Nodular Basal Cell Carcinoma (BCC) Currently Underway in United States Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile ...

1 month ago · proactiveinvestors.com

Medicus Pharma unveils ex-GSK and Pfizer senior as chief medical officer

Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) Ltd has announced the appointment of Faisal Mehmud, formerly of GSK PLC (LSE:GSK, NYSE:GSK) and Pfizer Inc (NYSE:PFE, ETR:PFE), as chief medical officer. Mehmu...

1 month ago · proactiveinvestors.com

Medicus Pharma makes debut on Nasdaq raising $4M to advance skin cancer trial - ICYMI

Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) CEO and chairman Raza Bokhari joined Proactive to discuss the company's recent listing on the Nasdaq, a key milestone for the biotechnology firm. Following the...

2 months ago · newsfilecorp.com

Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States

Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 15, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") today announced the closing of its previously ann...

2 months ago · proactiveinvestors.com

Medicus Pharma announces pricing of US IPO

Medicus Pharma (TSX-V:MDCX) announced the pricing of its US initial public offering (IPO), with 970,000 units priced at $4.125 per unit. Each unit will comprise one common share and one warrant, which...

2 months ago · newsfilecorp.com

Medicus Pharma Ltd. Announces Pricing of US$4.0M Initial Public Offering in the United States

Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 13, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") today announced the pricing of its initial public...

2 months ago · newsfilecorp.com

Medicus Pharma Ltd. Announces Share Consolidation in Anticipation of Proposed U.S. Listing

Toronto, Ontario--(Newsfile Corp. - October 28, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") today announced that it has completed a consolidation of its common shares on a 2-to...